Clinical trials

Condition   Drug Name  
Study Minocycline, clindamycin and hydrocortisone in non-small cell lung cancer: The LUTRAERL (NCT00473083) study
Design Randomized; Open
Patients 150
Treatment Regimen Minocycline, 100 mg p.o. b.i.d. x 4 wks; Clindamycin 2% lotion top.; Hydrocortisone 1% lotion top.
Conclusions The efficacy of minocycline, clindamycin and hydrocortisone in reducing erlotinib-induced rash in patients with non-small cell lung cancer will be determined in a phase II study to be initiated in June 2007
Reference(s) Systemic and topical treatments for rash secondary to erlotinib in lung cancer (LUTRAERL) (NCT00473083) Web Site 2007